KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Short-term Investments (2018 - 2025)

Historic Short-term Investments for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $157.7 million.

  • Adaptive Biotechnologies' Short-term Investments fell 2314.79% to $157.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.7 million, marking a year-over-year decrease of 2314.79%. This contributed to the annual value of $174.4 million for FY2024, which is 3801.95% down from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Short-term Investments is $157.7 million, which was down 2314.79% from $154.7 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Short-term Investments' 5-year high stood at $540.6 million during Q1 2021, with a 5-year trough of $142.8 million in Q1 2025.
  • For the 5-year period, Adaptive Biotechnologies' Short-term Investments averaged around $275.7 million, with its median value being $281.3 million (2023).
  • Examining YoY changes over the last 5 years, Adaptive Biotechnologies' Short-term Investments showed a top increase of 10212.11% in 2021 and a maximum decrease of 6211.34% in 2021.
  • Over the past 5 years, Adaptive Biotechnologies' Short-term Investments (Quarter) stood at $214.0 million in 2021, then soared by 90.74% to $408.2 million in 2022, then crashed by 31.07% to $281.3 million in 2023, then tumbled by 38.02% to $174.4 million in 2024, then fell by 9.54% to $157.7 million in 2025.
  • Its last three reported values are $157.7 million in Q3 2025, $154.7 million for Q2 2025, and $142.8 million during Q1 2025.